Apollo Hospitals Q1FY27: Broad-Based Growth & Strategic Expansion

$APOLLOHOSP registered a 21% year-over-year increase in consolidated revenue to ₹7,044 crore for Q1FY27. Net profit surged 34% YoY to ₹581 crore, while EBITDA rose 28% to ₹1,092 crore with margins expanding to 15.5%. Robust Core Healthcare Growth: The primary hospital business grew 22% YoY to ₹3,567 crore, buoyed by a 13% rise in inpatient volume and 70% occupancy. Established facilities delivered a solid 25.9% EBITDA margin, offsetting temporary operational losses from new hospital facilities. Narrowing Digital & Insurance Losses: Apollo HealthCo revenue jumped 20% to ₹2,977 crore, with EBITDA climbing 83% to ₹171 crore. Apollo 24/7 reduced its quarterly cash losses dramatically from ₹49 crore to ₹10 crore (aiming for Q2 break-even), while the insurance arm targets break-even by Q3FY27. Diagnostic & Wellness Momentum: Apollo Health and Lifestyle Ltd (AHLL) posted a 15% revenue gain to ₹500 crore and narrowed net losses to ₹1 crore. Diagnostic revenues expanded 31%, heavily supported by a ~38% YoY surge in wellness offerings. Aggressive Long-Term Capacity Expansion: Management projects ~20% hospital revenue growth for FY27. Operations expanded with a 180-bed Sarjapur facility, a Gurugram launch slated for Q3FY27, and plans to scale total bed capacity to ~14,100 by FY31. Valuation & Regulatory Considerations: Despite strong operational visibility, potential regulatory risks surrounding price caps on private healthcare could weigh on valuations. Given the stock's ~25% year-to-date rally (trading at ~24x FY28e EV/EBITDA), analysts recommend booking partial profits with an Equal-weight stance.